Tonix Pharmaceuticals Holding Corp. — Director's Dealing 2020

May 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK: 0001430306
Period of Report: 2020-05-04

Reporting Person: SAENGER BRADLEY (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-04	Stock Option	$0.77	A	360000	Acquired	2030-05-04	Common Stock (360000)	Direct
2020-05-04	Stock Option	$0.96	A	360000	Acquired	2030-05-04	Common Stock (360000)	Direct

Footnotes

F1: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.

F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.